Half-year report · Q2
7776.TEDINET S100WJ5L
Period2025-01-01 → 2025-06-30
Filed2025-08-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥37m | 2025-01-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥193m | 2024-01-01 → 2024-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥76m | 2024-01-01 → 2024-06-30 | Standalone | Net sales |
| Operating income | −¥623m | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Operating income | −¥464m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Ordinary income | −¥624m | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥848m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥463m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥651m | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥473m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Net income | −¥651m | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | −¥860m | 2024-01-01 → 2024-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥474m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥2.4bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.4bn | at 2024-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥400m | at 2025-06-30 | Standalone | Liabilities |
| Total liabilities | ¥270m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.5bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.1bn | at 2024-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥473m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥866m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥405m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥717,000 | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥18m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | −¥4m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥855m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥422m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-18.78 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.72 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.74 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 78.5% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.4% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 34,666,419 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 34,666,419 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 33,447,119 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥115m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥449m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥35m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥35m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥59m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥37m |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥37m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥508m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥113m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥332m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥75m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥75m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥19m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥76m |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥76m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | −¥351m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 429
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | CurrentYTDDuration_NonConsolidatedMember | -717000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration_NonConsolidatedMember | -3750000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration_NonConsolidatedMember | -4375000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration_NonConsolidatedMember | 425977000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration_NonConsolidatedMember | 422227000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration_NonConsolidatedMember | -4375000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration_NonConsolidatedMember | 10987000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration_NonConsolidatedMember | -478136000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 2163292000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 2134299000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant_NonConsolidatedMember | 2174279000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant_NonConsolidatedMember | 1656163000 | JPY |
| Directors compensations sga | Prior1YTDDuration_NonConsolidatedMember | 11160000 | JPY |
| Directors compensations sga | CurrentYTDDuration_NonConsolidatedMember | 18090000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration_NonConsolidatedMember | 42249000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration_NonConsolidatedMember | 35115000 | JPY |
| Bonuses sga | Prior1YTDDuration_NonConsolidatedMember | 9245000 | JPY |
| Bonuses sga | CurrentYTDDuration_NonConsolidatedMember | 8686000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration_NonConsolidatedMember | 1865000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration_NonConsolidatedMember | 1761000 | JPY |
| Compensations sga | Prior1YTDDuration_NonConsolidatedMember | 26060000 | JPY |
| Compensations sga | CurrentYTDDuration_NonConsolidatedMember | 35769000 | JPY |
| License fee sga | Prior1YTDDuration_NonConsolidatedMember | 8500000 | JPY |
| License fee sga | CurrentYTDDuration_NonConsolidatedMember | 5155000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 75086000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 1217000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 76303000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 76303000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 75086000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 1217000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 76303000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 76303000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | -18715000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | -332108000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -350824000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -113346000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | -464170000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 35123000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 1875000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 36998000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 36998000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |